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ABSTRACT 
Objective: The current study focuses on the anticoagulant and antiplatelet activities of aqueous seed extract of Jackfruit (AqSEJ). 
Methods: Anticoagulant effect of AqSEJ was tested using plasma recalcification time, mouse tail bleeding time, Activated Partial Thromboplastin 
Time (APTT) and Prothrombin Time (PT). Antiplatelet activity was examined by platelet aggregation studies using agonists such as ADP, Collagen 
and Epinephrine. 
Results: The AqSEJ enhanced the clotting time of citrated human plasma from control 200±10 s to 740±14 s. The anticoagulant activity of AqSEJ 
was further strengthened by in-vivo mouse tail bleeding assay. The i. v. injection of AqSEJ significantly prolonged the bleeding time in a dose 
dependent manner. The recorded bleeding time was>10 min (P<0.01) at the concentration of 30 μg against the PBS treated control of 1.48±0.10 min 
with the IC50 values 37.5 μg/ml and 47.5 μg/ml respectively. Interestingly, AqSEJ specifically prolonged the clot formation process of only APTT but 
not PT, revealing the anticoagulation triggered by the extract could be due to its interference in an intrinsic pathway of the blood coagulation 
cascade. Furthermore, AqSEJ inhibited the agonists such as ADP, epinephrine and collagen induced platelet aggregation of about 66.7%, 39.2% and 
37.0% respectively at the concentration of 200 μg. 
Conclusion: AqSEJ showed anticoagulant and antiplatelet activities. Hence, it may serve as a better alternative for thrombotic disorders.  
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INTRODUCTION 
Thrombotic disorders such as arterial thrombosis, atrial fibrillation, 
myocardial infarction/heart attack, unstable angina, deep vein 
thrombosis, pulmonary embolism and cerebral stroke increases the risk 
of cardiovascular/cerebrovascular complications and represent a major 
health problem worldwide including India. There are about 10 million 
cases annually reported exceeding the number of deaths from cancer 
and other diseases. It is estimated that the annual mortality rate of 
60,000 in the United States and more than 50,000 in India. It is to note 
that, anticoagulants those inhibits the clot formation by blocking the 
action of clotting factors/coagulation factors and ant platelet agents 
those blocks the formation of blood clot by preventing the clumping of 
platelets are extensively being used in the treatment of thrombotic 
disorders [1, 2]. Thus, anticoagulant and ant platelet therapy is the 
effective therapy for the prevention and treatment of thrombotic 
disorders. While, the currently established anticoagulants such as, 
warfarin, dabigatran, unfractionated heparin (UFH), enoxaparin, 
fondaparinux, bivalirudin (thrombin inhibitors), low molecular weight 
heparin and antiplatelet agents such as, aspirin, thienopyridines, 
dipyridamole, dlopidogrel, dpoprostenol, abciximab, eptifibatide and 
tirofiban (glycoprotein IIb/IIIa inhibitors) are having numerous 
limitations with several side effects, including lack of reversibility, a 
sheer dose response, food and multiple drug-drug interactions, narrow 
therapeutic index, internal bleeding, birth defects and miscarriage [3-6]. 
Therefore, identifying the novel anticoagulant and ant platelet agents 
from the natural sources with least side effects is the challenging task to 
the researchers. In addition, the other hypothesis is that targeting 
coagulation cascade upstream from the common pathway provides a 
reduction in thrombin generation slow down the formation of fibrin clot 
or thrombosis. Investigating the target specific (factor Xa and thrombin) 
anticoagulant and ant platelet agents from the natural sources with least 
side effects helps in the better management of thrombotic disorders. 
Jackfruit seeds are richest sources of try sin, chymotrypsin, elastase 
inhibitors and lectin family glycoprotein’s (Jacalin) [7-9]. Jackfruit seeds 
were found to exhibit anticancer, antihypertensive, antiulcer, 
antioxidant, antifungal, and antimicrobial properties [10-12]. In our 
previous study, characterization of is forms of proteases (serine and 
cysteine) and their ability to hydrolyze fibrinogen and fibrin clot was 
reported from the aqueous Jackfruit seed extract (AqSEJ) [13]. However, 
in the current study, the anticoagulant and antiplatelet activity of AqSEJ 
was investigated further and the results are presented.  
MATERIALS AND METHODS 
Materials 
Collagen type-I, ADP, epinephrine were purchased from Sigma 
Chemicals Company, St. Louis, USA. UNIPLASTIN, LIQUICELIN-E and 
FIBROQUANT were purchased from Tulip Diagnostics Pvt. Ltd., Goa, 
India. All other chemicals and reagents used were analytical grade. 
Fresh blood sample was collected from healthy human donors. Swiss 
Wister albino mice weighing 20–25 g from the central animal house 
facility, Department of Studies in Zoology, University of Mysore, 
Mysore, India. Animal care and handling complied with the National 
Regulation for Animal Research. 
Jackfruit seeds 
Artocarpusheterophyllus Lam (Jackfruit) seeds were obtained in the 
month of April and May from Pittenahalli village, Tumkur district 
and identified by Dr. P. Sharanappa, University of Mysore. A voucher 
specimen (PS/52/18 FEB 2012)has been preserved at the 
herbarium of Bioscience Department, University of Mysore, Hassan 
PG campus, Hassan for future reference.  
Preparation of jackfruit seed extract 
Brown coat was removed from the Jackfruit seeds thoroughly 
chopped and homogenized using double distilled water and 
centrifuged at 2000 g for 20 min at 4 °C. The supernatant was 
collected and proteins were precipitated using 30% of ammonium 
sulphate. The precipitated protein sample was again centrifuged at 
3,500 g for 20 min, pellet was dissolved and dialyzed overnight. The 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 7, Supple 1, 2015 
Innovare 
Academic Sciences 
Sannaningaiah et al. 
Int J Pharm Pharm Sci, Vol 7, Supple 1, 187-191 
188 
“Drugs from Nature: Plants as an important source of pharmaceutically important metabolites”  
Guest Editor: Dr. Dhananjaya Bhadrapura Lakkappa 
protein sample obtained was stored at-20 °C until use. This 
extracted protein sample was used throughout the study and 
referred as aqueous seed extract of Jackfruit (AqSEJ). 
Anticoagulant activity 
Plasma recalcification time 
The plasma recalcification time was determined as described earlier 
[14]. Briefly, the AqSEJ (0-50 μg) was pre-incubated with 0.2 ml of 
citrated human plasma in the presence of 10 mMTrisHCl (20 μl) 
buffer pH 7.4 for 1 min at 37 °C. Then 0.25 M CaCl2 (20 μl) was 
added to the pre-incubated mixture and clotting time was recorded.  
Bleeding time 
The bleeding time was assayed as described previously [15]. Briefly, 
AqSEJ(0-50 μg) in 30 μl of PBS was injected intravenously through 
the tail vein of a group of five mice. After 10 min, mice were 
anaesthetized using diethyl ether and a sharp cut of 3 mm length at 
the tail tip of a mouse was made. Immediately, the tail was vertically 
immersed into PBS which is pre-warmed to 37 °C. Bleeding time was 
recorded from the time bleeding started till it completely stopped 
and it was followed for 10 min.  
Activated partial thromboplastin time (APTT) and prothrombin 
time (PT) 
Briefly, 100 μl of normal citrated human plasma and AqSEJ (0-50 μg) 
were pre-incubated for 1 min. APTT and PT were carried out 
according to the manufacturer protocol using the coagulation 
analyzer (Labitec, Germany). For APTT, 100 μl of LIQUICELIN-E 
phospholipids preparation derived from Rabbit brain with ellagic 
acid was added. The clotting was initiated by adding 100 μl of 0.02 M 
CaCl2and the clotting time was measured. For PT, the clotting was 
initiated by adding 200 μl of PT reagent (UNIPLASTIN–rabbit brain 
thromboplastin). The time taken for the visible clot was recorded in 
seconds. The APTT ratio and the international normalized ratio 
(INR) for PT at each point were calculated from the values of control 
plasma incubated with the buffer for an identical period of time. 
Preparation of platelet-rich plasma and platelet-poor plasma  
The method of Ardlie and Han [16] was employed for the preparation 
of human platelet-rich plasma (PRP) and platelet-poor plasma (PPP). 
The platelet concentration of PRP was adjusted to 3.1×108 
platelets/ml with PPP. The PRP maintained at 37oC was used within2 
h for the aggregation process. All the above preparations were carried 
out using plastic wares or siliconizedglass wares. 
Platelet aggregation 
The turbid metric method of Born [17] was followed using a 
Chronology dual channel whole blood/optical lumi aggregation 
system (Model-700). Aliquots of PRP were pre-incubated with various 
concentrations of AqSEJ(0–200 µg) in 0.25 ml reaction volume. The 
aggregation was initiated independently by the addition of agonists, 
such as collagen, ADP and epinephrine and followed for 6 min. 
In-vitro platelet viability and platelet count 
The method of Kropotkin et al. [18] was used to test the platelet viability 
by incubating the PRP with various concentrations of AqSEJ(0–500 µg), 
and the platelet morphology was studied with a microscope using a 
Neubauer chamber. The data expressed as percentage viability, 
considering 100% viability in the absence of AqSEJ (control). 
Determination of endogenously generated reactive oxygen 
species (ROS)  
The endogenous Reactive Oxygen Species (ROS) in totalis determined 
according to the method of Li et al. [19]. In particular, H2O2 is determined 
according to the method of Barja [20]. PRP containing 1×105 platelets 
were diluted with 4-(2-hydroxyethyl)-1-piperazineethanesulfonicacid-
buffered saline was incubated with different concentrations of AqSEJ (0–
500 µg) at37oCfor 15 min in a microtiter plate. Then, 100 
µmol/lhomovanillic acid was added to the mixture and incubated for 30 
min at room temperature. The fluorescence was recorded using a 
fluorescence plate reader by exciting the samples at 312 nm and the 
resulting fluorescence was measured at 420 nm. 
Statistical analysis 
The data are presented as mean±SEM of at least five animals in each 
group. Difference among the data were determined by one-way 
analysis of variance (ANOVA) followed by Duncan’s Multiple Range 
Test (DMRT). Data were considered different at P<0.01. 
RESULTS AND DISCUSSION 
In our previous study, fibrin (ogen) olytic and non-toxic properties of 
AqSEJ was reported [13]. In the current study, anticoagulant and ant 
platelet proprieties of AqSEJ was carried out and the results are 
presented. AqSEJ showed strong anticoagulant effect in both in-vitro 
and in-vivo experiments. AqSEJ prolonged the clotting time of citrated 
human plasma from control 200±10 s to 740±14 s at the 
concentration of 20 μg (fig. 1). Furthermore, anticoagulant activity of 
AqSEJ was confirmed in-vivo by tail bleeding assay. The i. v. injection 
of AqSEJ significantly prolonged the bleeding time in a dose dependent 
manner. The recorded bleeding time was>10 min (P<0.01) at the 
concentration of 30 μg against the PBS treated control of 1.48±0.10 
min with the IC50 values 37.5 μg/ml and 47.5 μg/ml respectively (fig. 
2). Activated Partial Thromboplastin Time (APTT) and Prothrombin 
Time (PT) identify the efficacy/defect of the blood coagulation cascade 
that includes intrinsic, extrinsic and common pathways. Interestingly, 
AqSEJ specifically prolonged the clot formation process of only APTT 
but not PT revealing the anticoagulation triggered by the extract could 
be due to its interference in an intrinsic pathway of the blood 
coagulation cascade (table 1). 
 
 
Fig. 1: Effect of AqSEJ on plasma recalcification time: (A) AqSEJ 
(2–50 μg) was pre-incubated with 0.2 ml of citrated human 
plasma in the presence of 20 μl10 Mm Tris–HCl buffer pH 7.4 
for 1 min at 37 °C. 20 μl of 0.25 M CaCl2 was added to the pre-
incubated mixture and clotting time was recorded 
 
 
Fig. 2: Effect of AqSEJ on the bleeding time: Tail bleeding time 
was measured 10 min after intravenous administration of PBS 
or various doses of AqSEJ. Each point represents the mean±SD 
of three independent experiments, P<0.01. Bleeding time 
longer than 10 min was expressed as>10 min
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Table 1: Dose dependent effect of Jack fruit seed extract on clotting time of normal human plasma 
JFSE in µg PT clotting time in sec PT (INR values) APTT clotting time in sec APTT ratio 
0 16.09±0.02 1.05±0.02 46.05±0.05 1.00±0.02 
2 17.10±0.03 1.15±0.02 56.30±0.02 1.22±0.01 
4 20.40±0.02 1.31±0.01 63.20±0.07 1.37±0.04 
8 20.10±0.01 1.31±0.01 78.41±0.03 1.71±0.05 
12 22.06±0.02 1.44±0.01 91.20±0.01 1.98±0.02 
16 23.12±0.01 1.50±0.01 96.08±0.03 2.08±0.01 
20 21.05±0.03 1.37±0.02 100.10±0.05 2.15±0.03 
30 23.25±0.02 1.50±0.02 123.52±0.01 2.67±0.02 
40 21.09±0.04 1.37±0.02 132.10±0.04 2.87±0.02 
50 22.04±0.02 1.44±0.02 148.25±0.01 3.22±0.01 
 
Homeostasis is a physiological process that drives immediate 
response to the external injury. It operates through complex system 
of two pathways, the contact activation pathway (intrinsic pathway) 
and the tissue factor pathway (extrinsic pathway). These pathways 
may proceed independently or together but culminate in the 
common pathway that is conversion of prothrombin (factor II) into 
thrombin (factor IIa). Thrombin hydrolyzes fibrinogen and converts 
it into fibrin clot that helps in the arrest of bleeding. Further the 
fibrin clot will be hydrolyzed by fibrinolytic enzyme the plasmin that 
facilitates the easy flow of blood in the arteries and helps in the 
wound healing. Thus homeostasis is a highly regulated path way and 
it has a strong balance between natural procoagulant, anticoagulants 
and fibrinolytic factors. While, Impairment of homeostasis leads to 
the hyperactivation of the coagulation factors of the said pathways is 
the major culprit for the thrombotic disorders. Anticoagulants from 
the natural sources are the preferable weapons for curing 
thrombotic disorders. Several anticoagulant agents from natural 
sources with their mechanism of action were reported from the 
various research groups. For instance, the anticoagulant from snake 
venom (Ancrod), fungi aspergillusoryzae (Brinase), coumarin 
derivative from sweet clover (acenocoumarol), hirudin derivative 
from siliva of leech (Bialirudin) are currently being used to treat 
thrombotic disorders (21-24).  
Platelet activation by several physiological agonists namely, 
collagen, ADP, thrombin, epinephrine and platelet activating factor 
play a crucial role in the primary hemostasis. However, like 
coagulation factors hyper activation of the platelets due to 
genetic/environmental factors contribute equally for the thrombotic 
disorders. Eptifibatide, derivative from rattle snake venom that 
inhibits glycoprotein IIb/IIIa receptor on platelets is currently using 
in the treatment of coagulation disorders (21). In order to study the 
interference of AqSEJ on platelet function, platelet aggregation was 
analyzed using agonists such as ADP, epinephrine and collagen using 
platelet-rich plasma. AqSEJ inhibited the agonists such as ADP, 
epinephrine and collagen induced platelet aggregation of about 
66.7%, 39.2% and 37.0% respectively at the concentration of 200 
μg(fig. 3,4,5). Among agonists examined AqSEJ inhibited in the order 
of ADP>epinephrine>collagen induced aggregation. The respective 
IC50 values are given in the table 2. 
  
 
Fig. 3: Platelet aggregation was initiated by adding ADP as an agonist. (A)Traces of platelet aggregation: Trace 1 (ADP 10 µM); Trace 2 
(ADP 10 µM+50 μg of AqSEJ); Trace 3 (ADP 10 µM+100 μg of AqSEJ); Trace 4 (ADP 10 µM+200 μg of AqSEJ). The values represent±SD of 
three independent experiments. (B) Dose dependent platelet aggregation %. (C) Dose dependent platelet aggregation inhibition % 
 
Table 2: IC50 values of agonists collagen, thrombin, ADP, and epinephrine-induced platelet aggregation 
S. No. Name of the agonists IC50values of AqSEJ (PRP) concentration (mg/ml) 
01 ADP 0.488 
02 Collagen 1.080 
03 Epinephrine 1.020 
ADP, adenosine diphosphate; PRP, platelet-rich plasma 
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Fig. 4: Platelet aggregation was initiated by adding Epinephrine as an agonist. Trace 1 (Epinephrine 5µM); Trace 2 (Epinephrine 5µM+50 
μg of AqSEJ); Trace 3 (Epinephrine 5µM+100 μg of AqSEJ); Trace 4 (Epinephrine 5µM+200 μg of AqSEJ). The values represent±SD of three 
independent experiments. (B) Dose dependent platelet aggregation %. (C) Dose dependent platelet aggregation inhibition % 
 
 
Fig. 5: Platelet aggregation was initiated by adding collagen as an agonist. (A)Trace 1 (Collagen 2 µg/ml); Trace 2(Collagen 2 µg/ml+50 μg 
of AqSEJ); Trace 3 (Collagen 2 µg/ml+100 μg of AqSEJ); Trace 4 (Collagen 2 µg/ml+200 μg of AqSEJ). The values represent±SD of three 
independent experiments. (B) Dose dependent platelet aggregation %. (C) Dose dependent platelet aggregation inhibition % 
 
Although, the observed ant platelet activity of AqSEJ could be due to 
the participation of proteolysis enzyme/try sin inhibitors, it is too 
preliminary to say its exact mechanism of action. Ethanolic extracts 
of Acheranthusaspera (leaves), Tridaxprocumbens(whole plant), 
aqueous extract of Abutilon indicum(leaves), Acheranthusaspera 
(whole plant), Soshiho-tang, Cannabis and dicoumarin from Viola 
yedoensis Makino, Phenanthrenes and flavonoids from 
Calanthearisanensis (leaves), Artocarpuscommunis (root cortex) 
found to exhibit ant platelet activity [25-31].  
Furthermore, AqSEJ was tested for its probable role on the 
generation of Reactive Oxygen Species (ROS), in particular 
superoxide radical and hydrogen peroxide. Interestingly, AqSEJ did 
not alter the level of ROS in both PRP and washed platelets up to the 
tested dose of 500 µg. It is known fact that the process of platelet 
aggregation constantly escorted through preliminary shape change 
and generation of Reactive oxygen species (ROS). Nonetheless, 
AqSEJ did not generate ROS, while inhibited ADP, epinephrine and 
collagen induced platelet aggregation the observed event could be 
due to receptor mediated but not through the change in the platelet 
shape. It’s indeed very interesting to sightsee whether AqSEJ 
blocking agonists or hydrolyzing the platelet surface receptors. 
CONCLUSION 
In conclusion, this study for the first time attempted to sight seethe 
anticoagulant and ant platelet properties of AqSEJ. Hence, further 
identification and biochemical characterization of active molecule 
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from the AqSEJ, may present a promising alternative in the 
treatment of thrombotic disorders. 
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